These results demonstrate that CTRP1 could improve glucose homeostasis and prevent HFD-induced obesity and fatty liver through upregulating the energy expenditure and reducing food intake, suggesting CTRP1 may serve as a promising target for treating metabolic diseases. This evidence concerns the gene C1QTNF1 and obesity due to melanocortin 4 receptor deficiency.